Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 582

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 582
---
 Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg Ex-U.S.Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1) an up-frontlicense fee of $ 2.0million, (2) upon the Company’s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $ 13.0million, (3) certain royalties in the mid-singledigit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Royalty Term, with a quarterly minimum royalty of $ 150,000, and (4) pursuant to the amendment thereto, (a) certain royalties at rates in the low-singledigit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg Ex-U.S.Territory during the Romeg Ex-U.S.Territory Royalty Term and (b) a one-time, non-refundable, non-creditablepayment of $ 700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267shares of Common Stock. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $ 5.7million, which is comprised of the upfront license fee of $ 2.0million and deferred consideration of $ 3.7 million that is the present value of the future minimum royalty payments and immaterial transaction costs. For each of the three months ended September 30, 2025 and 2024, the Company made royalty payments in the amount of $ 0.2 million. For each of the nine months ended September 30, 2025 and 2024, the Company made royalty payments in the amount of $ 0.5million. No contingent consideration was recognized as a liability or included in the fair value of the assets as of September 30, 2025 or December 31, 2024. ELYXYB Acquisition In February 2023, the Company entered into an asset purchase agreement (the “ELYXYB APA”) with BioDelivery Sciences International, Inc. (“BDSI”) and Collegium Pharmaceutical, Inc. (“Collegium